

● PRINTER RUSH ●

(PTO ASSISTANCE)

Application : <u>09/615285</u>	Examiner : <u>Nickol</u>	GAU : <u>1642</u>
From : <u>he</u>	Location : <u>(IDC) FMF FDC</u>	Date : <u>9/20/05</u>
Tracking # : <u>01608 3864</u>		Week Date : <u>3/14/05</u>

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input checked="" type="checkbox"/> SPEC	_____	

[RUSH] MESSAGE: Paragraph of text under tables on page 106 refer to
bolding. Is the bolding supposed to be in the tables? If so,
could you please indicate where because you can't tell.

Thank you.

[XRUSH] RESPONSE: Attorney advised as to which entries were
boldface. Attached is a marked-up copy of the
page: "B —" is handwritten under items to be
printed in boldface. No clearer copy of the original
page is available.

INITIALS: def

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.
 REV 10/04

TABLES

Table 1. Immunohistochemical staining of human tissues with anti-TMPRSS2 monoclonal antibody.

Staining Intensity	Tissue	Predominant Staining Localization	
		Cytoplasmic	Luminal surface/secretion
5			
10	None		
	Kidney		
	Skin		
	Lung		
	Liver		
	Testis		
	Spleen		
15	Light		
	Fallopian tubes	+	
	Colon cancer (1/4)	+	+
20	Moderate to strong		
	Prostate (7/7)	+	+
	BPH (7/7)	+	+
	PIN (1/1)	+	+
	Colon (4/4)	+	
	Pancreas (4/4)	+	
25	Prostate cancer (5/5)	+	+
	Colon cancer (3/3)	+	+

Table 2: Epitope mapping of anti-TMPRSS2 mAbs

test mAb	none	competitor mAb						
		1F9	2D10	2F8	3G3	6B11	8C6	9G8
30	1F9-B	2.371±0.012	0.269±0.001	0.730±0.004	2.230±0.037	0.359±0.005	0.353±0.008	2.625±0.033
	2F8-B	1.390±0.015	1.258±0.020	1.169±0.005	0.407±0.032	1.250±0.009	1.242±0.020	0.371±0.005
35	8C6-B	1.512±0.004	1.899±0.013	1.434±0.031	1.216±0.062	1.803±0.044	1.806±0.056	0.161±0.005
								1.473±0.014

A decrease in signal intensity of the biotinylated antibody in the presence of an excess of unlabelled antibody indicates that the mAbs compete for the same or overlapping binding sites (shown in bold). As indicated in Table 2 a decrease in signal intensity of biotinylated 1F9 (1F9-B) is seen in the presence of mAbs 2D10, 3G3, and 6B11, and itself, but not by 2F8, 8C6, and 9G8. These results indicate that mAbs 1F9, 2D10, 3G3, 6B11 share the same (or overlapping) epitope that is distinct from those of 2F8, 8C6, and 9G8. MAb 2F8-B is competed by itself and by mAbs 8C6 and 9G8 indicating these mAbs share the same or overlapping epitopes. MAb 8C6-B is competed by itself and moderately by mAb 2F8. Taken together, these results indicate that the panel of anti-TMPRSS2 antibodies recognize different epitopes within the protease domain of TMPRSS2.